Abstract
128 12 hrs urine collections were made in patients presenting with central PP receiving the GnRH agonist B, either subcutaneously (SC) (13 girls and 5 boys) or intranasally (IN) (7 girls and 4 boys). Centers from Belgium, France, Germany, Holland and Switzerland participated in this study. Urinary excretion of immunoreactive B and B metabolites measured after SC administration of 20μg/kg once a day in 14 girls with good control was 88.5 ± 7.5μg (mean ± SEM) during the first 12hrs and 6.0±1.2μg during the following 12hrs. Mean E2 levels under therapy was 8.9±0.9pg/ml. 6 girls receiving 20μg/kg t.i.d. has an excretion of 91.5±8.7 and 89.5±9.2μg/12hrs, respectively. Two girls with poor control showed excretion levels similar to those with good control. In the 5 boys treated SC, similar levels to those measured in girls were found. One of them remained resistant (T>3.8ng/ml). In the 5 girls and 4 boys receiving IN 28.7±1.5μg/day of B, urinary excretion was 4.3±0.9μg/12hrs during daytime and 2.9±0.8μg during nighttime. Clinical control was poor in 2 girls: both had excretion values of 0.004 and 0.093μg, and 0.001 and 0.081μg/12hrs, suggesting a poor compliance or a non-absorption by the nasal mucosa. In a third one with Albright's syndrome, resistance to therapy was observed with B excretion of 1.4 and 1.1μg/12hrs. Measurement of B excretion is of value for the evaluation of control of the therapy, compliance or resistance, particularly when B is administered IN.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sizonenko, P., Reznik, Y. & Aubert, M. URINARY EXCRETION OF BUSERELIN (B) DURING THERAPY OF CENTRAL PRECOCIOUS PUBERTY (PP). A MULTICENTER STUDY. Pediatr Res 20, 1198 (1986). https://doi.org/10.1203/00006450-198611000-00147
Issue date:
DOI: https://doi.org/10.1203/00006450-198611000-00147
